Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
CYTR's Cash to Debt is ranked higher than
87% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. CYTR: No Debt )
CYTR' s 10-Year Cash to Debt Range
Min: 2.95   Max: No Debt
Current: No Debt

Equity to Asset 0.79
CYTR's Equity to Asset is ranked higher than
81% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CYTR: 0.79 )
CYTR' s 10-Year Equity to Asset Range
Min: 0.16   Max: 0.96
Current: 0.79

0.16
0.96
Interest Coverage No Debt
CYTR's Interest Coverage is ranked higher than
70% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYTR: No Debt )
CYTR' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 4.47
M-Score: 42.57
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -49605.00
CYTR's Operating margin (%) is ranked lower than
53% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. CYTR: -49605.00 )
CYTR' s 10-Year Operating margin (%) Range
Min: -49606   Max: -21.16
Current: -49605

-49606
-21.16
Net-margin (%) -30117.00
CYTR's Net-margin (%) is ranked lower than
53% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. CYTR: -30117.00 )
CYTR' s 10-Year Net-margin (%) Range
Min: -30118   Max: 408
Current: -30117

-30118
408
ROE (%) -44.57
CYTR's ROE (%) is ranked higher than
67% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. CYTR: -44.57 )
CYTR' s 10-Year ROE (%) Range
Min: -342.91   Max: 1.39
Current: -44.57

-342.91
1.39
ROA (%) -33.88
CYTR's ROA (%) is ranked higher than
68% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. CYTR: -33.88 )
CYTR' s 10-Year ROA (%) Range
Min: -201.4   Max: 1.13
Current: -33.88

-201.4
1.13
ROC (Joel Greenblatt) (%) -10482.88
CYTR's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. CYTR: -10482.88 )
CYTR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12894.39   Max: -45.66
Current: -10482.88

-12894.39
-45.66
Revenue Growth (3Y)(%) -100.00
CYTR's Revenue Growth (3Y)(%) is ranked higher than
52% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CYTR: -100.00 )
CYTR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 188.4
Current: -100

-100
188.4
EBITDA Growth (3Y)(%) -10.30
CYTR's EBITDA Growth (3Y)(%) is ranked higher than
71% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. CYTR: -10.30 )
CYTR' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -67.3   Max: 144.7
Current: -10.3

-67.3
144.7
EPS Growth (3Y)(%) -11.70
CYTR's EPS Growth (3Y)(%) is ranked higher than
73% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CYTR: -11.70 )
CYTR' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 94.8
Current: -11.7

-55.3
94.8
» CYTR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CYTR Guru Trades in

Q4 2013

CYTR Guru Trades in Q4 2013

Steven Cohen 205,100 sh (New)
» More
Q1 2014

CYTR Guru Trades in Q1 2014

George Soros 81,800 sh (New)
Paul Tudor Jones 51,898 sh (New)
Steven Cohen Sold Out
» More
Q2 2014

CYTR Guru Trades in Q2 2014

Paul Tudor Jones Sold Out
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CYTR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.40
CYTR's P/B is ranked higher than
73% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. CYTR: 4.40 )
CYTR' s 10-Year P/B Range
Min: 1.3   Max: 64.65
Current: 4.4

1.3
64.65
P/S 2789.24
CYTR's P/S is ranked lower than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. CYTR: 2789.24 )
CYTR' s 10-Year P/S Range
Min: 0   Max: 2859.8
Current: 2789.24

0
2859.8
Current Ratio 4.68
CYTR's Current Ratio is ranked higher than
74% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. CYTR: 4.68 )
CYTR' s 10-Year Current Ratio Range
Min: 1.24   Max: 21.33
Current: 4.68

1.24
21.33
Quick Ratio 4.68
CYTR's Quick Ratio is ranked higher than
75% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. CYTR: 4.68 )
CYTR' s 10-Year Quick Ratio Range
Min: 1.24   Max: 21.33
Current: 4.68

1.24
21.33
Days Sales Outstanding 7.00
CYTR's Days Sales Outstanding is ranked higher than
97% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. CYTR: 7.00 )
CYTR' s 10-Year Days Sales Outstanding Range
Min: 2.32   Max: 7752.6
Current: 7

2.32
7752.6

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.80
CYTR's Price/Net Cash is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. CYTR: 4.80 )
CYTR' s 10-Year Price/Net Cash Range
Min: 0.55   Max: 108.24
Current: 4.8

0.55
108.24
Price/Net Current Asset Value 4.70
CYTR's Price/Net Current Asset Value is ranked higher than
89% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. CYTR: 4.70 )
CYTR' s 10-Year Price/Net Current Asset Value Range
Min: 0.54   Max: 108.89
Current: 4.7

0.54
108.89
Price/Tangible Book 4.20
CYTR's Price/Tangible Book is ranked higher than
79% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. CYTR: 4.20 )
CYTR' s 10-Year Price/Tangible Book Range
Min: 0.32   Max: 65.43
Current: 4.2

0.32
65.43
Earnings Yield (Greenblatt) -23.70
CYTR's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. CYTR: -23.70 )
CYTR' s 10-Year Earnings Yield (Greenblatt) Range
Min: -97   Max: 3114.3
Current: -23.7

-97
3114.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CX5N.Germany,
CytRx Corp is a Delaware corporation, incorporated in 1985. The Company is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. Tamibarotene is an orally available, synthetic retinoid, rationally designed to overcome resistance and reduce the toxic side effects of differentiation therapy with all-trans retinoic acid, a component of the current first-line treatment for acute promyelocytic leukemia, or APL. Bafetinib (formerly INNO-406) is an orally bioavailable, rationally-designed inhibitor of several Src kinases developed by the Japanese pharmaceutical company, Nippon Shinyaku, to overcome some of the limitations of Gleevec and other tyrosine kinase inhibitors in resistant chronic myelogenous leukemia. The Company do not have manufacture supplies of aldoxorubicin or any of our other product candidates accordingly it is dependent upon third-party manufactures, or potential future strategic alliance partners, to manufacture these supplies. The Company has manufacturing supply arrangements in place with respect to a portion of the clinical supplies needed for the clinical development programs for aldoxorubicin. The Company's plan is to establish its own sales force and marketing capability in order to commercialize aldoxorubicin in the U.S. and to seek a marketing partner for commercialization in other territories. It is subjected to a variety of federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.
» More Articles for CYTR

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CytRx Corporation (CYTR) Jumps: Stock Rises 11.3% - Tale of the Tape Apr 20 2015
8 Analyst Stocks Under $10 With Massive Upside Calls Apr 18 2015
CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation Apr 17 2015
Oppenheimer Jumps On CytRx Bandwagon Apr 17 2015
Top Analyst Upgrades and Downgrades: Apple, CyberArk, EMC, Goldman Sachs, SanDisk, ULTA, Wayfair and... Apr 17 2015
Coverage initiated on CytRx by Oppenheimer Apr 17 2015
CYTRX CORP Financials Mar 14 2015
Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization... Mar 11 2015
Dr. Anita J. Chawla Joins CytRx Board of Directors to Add Additional Drug Commercialization... Mar 11 2015
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers Mar 11 2015
CytRx reports 4Q loss Mar 10 2015
CytRx reports 4Q loss Mar 10 2015
CytRx Reports 2014 Financial Results Mar 10 2015
CYTRX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Mar 10 2015
CytRx Reports 2014 Financial Results Mar 10 2015
CytRx to Present at the Cowen & Company 35th Annual Health Care Conference Feb 25 2015
CytRx to Present at the Cowen & Company 35th Annual Health Care Conference Feb 25 2015
CytRx Announces Overall Survival Results from Its Global Phase 2b Clinical Trial of Aldoxorubicin in... Feb 11 2015
CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting... Feb 11 2015
CytRx to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015 in New York... Feb 02 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK